Doctor profile · Federal record
Dr. ROBERT BYRAM, FNP
Family Nurse Practitioner (CMS: NURSE PRACTITIONER) · Family Nurse Practitioner · NEW ORLEANS, LA
- NPI 1356528616
- Accepts Medicare
- 19 yrs in practice
- Licensed in 2 states
- Male
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
1415 TULANE AVE
NEW ORLEANS, LA 701122600
(504) 988-6300
fax (504) 988-6348 - Mailing address
-
1430 TULANE AVE, SUITE 8578
NEW ORLEANS, LA 701122632
Credentials & registration
- NPI registered
- January 2008 — 18 yrs on file
- Profile last updated
- April 8, 2014
- Year of graduation
- 2007 — 19 yrs since
- Specialty taxonomy
- 363LF0000X — NUCC code
- State licenses (2)
- Mississippi #R853885 · Louisiana #AP06172
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1356528616. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
115
Distinct HCPCS
4
Medicare allowed
$7,517
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
99214 |
Established patient office or other outpatient visit, 30-39 minutes | 63 | 30 | $83 | |
99212 |
Established patient office or other outpatient visit, 10-19 minutes | 27 | 22 | $30 | |
99213 |
Established patient office or other outpatient visit, 20-29 minutes | 13 | 13 | $54 | |
38222 |
Biopsy and aspiration of bone marrow sample for diagnosis | 12 | 11 | $64 |
In context: peer comparison
Among 77 peers in this city , average services per provider: 62. This provider delivers 1.9× the peer median.Open Payments
Industry payments received
All-time total
$1,757
Transactions
68
Manufacturers
15
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Incyte Corporation | 14 | $374.60 | |
| SOBI, INC | 7 | $242.81 | |
| Novartis Pharmaceuticals Corporation | 12 | $230.01 | |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $108.53 | |
| Astellas Pharma US Inc | 4 | $82.67 | |
| Alexion Pharmaceuticals, Inc. | 4 | $67.20 | |
| Rigel Pharmaceuticals, Inc. | 3 | $63.81 | |
| Janssen Biotech, Inc. | 3 | $59.66 | |
| Karyopharm Therapeutics Inc. | 3 | $53.49 | |
| GlaxoSmithKline, LLC. | 3 | $51.95 | |
| PharmaEssentia USA Corporation | 2 | $48.35 | |
| Adaptive Biotechnologies Corporation | 2 | $44.08 | |
| Apellis Pharmaceuticals, Inc. | 2 | $44.01 | |
| PFIZER INC. | 2 | $44.00 | |
| ABBVIE INC. | 2 | $36.50 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
1,023
Patients
195
Total drug cost
$8,009,905
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Acyclovir | Generic | 205 | 51 | $3,859 |
| Revlimid (Lenalidomide) | Brand | 203 | 32 | $4,612,299 |
| Sulfamethoxazole-Trimethoprim (Sulfamethoxazole/Trimethoprim) | Brand | 131 | 38 | $519 |
| Potassium Chloride | Generic | 59 | 29 | $857 |
| Rezurock (Belumosudil Mesylate) | Brand | 47 | 0 | $848,771 |
| Gabapentin | Generic | 46 | 12 | $618 |
| Prednisone | Generic | 45 | 0 | $212 |
| Dexamethasone | Generic | 44 | 19 | $881 |
| Jakafi (Ruxolitinib Phosphate) | Brand | 43 | 0 | $785,565 |
| Venclexta (Venetoclax) | Brand | 39 | 0 | $536,594 |